Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
PARP1 (Poly(ADP-Ribose) Polymerase 1)
i
Other names:
PARP1, Poly(ADP-Ribose) Polymerase 1, ADP-Ribosyltransferase (NAD+; Poly (ADP-Ribose) Polymerase), ADP-Ribosyltransferase Diphtheria Toxin-Like 1, Poly (ADP-Ribose) Polymerase Family, Member 1, Protein Poly-ADP-Ribosyltransferase PARP1, DNA ADP-Ribosyltransferase PARP1, NAD(+) ADP-Ribosyltransferase 1, Poly [ADP-Ribose] Polymerase 1, Poly[ADP-Ribose] Synthase 1, ADPRT 1, PARP-1, ADPRT, ARTD1, PPOL, ADP-Ribosyltransferase NAD(+), Poly(ADP-Ribosyl)Transferase, Poly(ADP-Ribose) Synthetase, PADPRT-1, ADPRT1, PARP
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
142
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
PARP1 mutation
Solid Tumor
PARP1 mutation
Solid Tumor
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
PARP1 underexpression + PBRM1 mutation
Renal Cell Carcinoma
PARP1 underexpression + PBRM1 mutation
Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
EGFR T790M + PARP1 mutation
Non Small Cell Lung Cancer
EGFR T790M + PARP1 mutation
Non Small Cell Lung Cancer
osimertinib
Resistant: C3 – Early Trials
osimertinib
Resistant
:
C3
osimertinib
Resistant: C3 – Early Trials
osimertinib
Resistant
:
C3
PARP1 expression
Esophageal Squamous Cell Carcinoma
PARP1 expression
Esophageal Squamous Cell Carcinoma
anlotinib
Sensitive: D – Preclinical
anlotinib
Sensitive
:
D
anlotinib
Sensitive: D – Preclinical
anlotinib
Sensitive
:
D
PARP1 overexpression
Breast Cancer
PARP1 overexpression
Breast Cancer
olaparib
Resistant: D – Preclinical
olaparib
Resistant
:
D
olaparib
Resistant: D – Preclinical
olaparib
Resistant
:
D
PARP1 underexpression
Soft Tissue Sarcoma
PARP1 underexpression
Soft Tissue Sarcoma
ATR inhibitor + PARP1 inhibitor
Sensitive: D – Preclinical
ATR inhibitor + PARP1 inhibitor
Sensitive
:
D
ATR inhibitor + PARP1 inhibitor
Sensitive: D – Preclinical
ATR inhibitor + PARP1 inhibitor
Sensitive
:
D
DNMT1 expression + PARP1 expression
Ovarian Cancer
DNMT1 expression + PARP1 expression
Ovarian Cancer
olaparib
Sensitive: D – Preclinical
olaparib
Sensitive
:
D
olaparib
Sensitive: D – Preclinical
olaparib
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.